· Venture Capital Tracker Editorial · investment-strategies
Precision Neuroscience Closes $250M Series D for Its Brain Interface
Precision Neuroscience closed an oversubscribed $250 million Series D, bringing total capital raised to $430 million as it advances a minimally invasive cortical interface toward broader clinical use.
Precision Neuroscience closed an oversubscribed $250 million Series D on September 24, 2026. The round brings total capital raised to $430 million.
Pershing Square Inc., the Ackman Oxman Institute and an undisclosed life-sciences investment fund co-led. Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL also participated.
Deal terms
| Field | Detail |
|---|---|
| Company | Precision Neuroscience |
| Financing | $250M oversubscribed Series D |
| Total raised | $430M |
| Co-leads | Pershing Square; Ackman Oxman Institute; undisclosed life-sciences fund |
| Valuation | Not disclosed |
| Status | Company-announced close |
The clinical milestone behind the round
Precision is developing a thin cortical electrode array designed to sit on the brain’s surface through a less invasive procedure than systems requiring electrodes to penetrate brain tissue. Its initial goal is to let people with paralysis control digital devices.
The company said its technology has been used in more than 100 patient procedures across 18 medical institutions. Those are company-reported operating figures, but they provide more evidence of clinical exposure than is typical for a private brain-computer interface company.
Precision’s Layer 7 Cortical Interface has received FDA clearance for temporary use. That is not the same as broad approval for a permanent commercial implant. The Series D will support additional clinical programs, engineering and commercialization work needed to close that gap.
What investors still cannot see
The company did not disclose its valuation, revenue, expected runway or the identity of the third co-lead. It also has not established that short-term procedural experience will translate into durable, safe long-term implantation at scale.
Brain-computer interfaces combine medical-device regulation, neurosurgical workflows, signal-processing performance and reimbursement. Capital can accelerate all four, but it cannot compress every clinical endpoint.
Bottom line
This is a confirmed $250 million Series D, not a research grant. The unusually large round gives Precision resources to pursue commercialization, while the core diligence question remains whether its minimally invasive design can produce reliable long-term control with an acceptable procedure and safety profile.
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.